We are building a pharmaceutical company focused on the science & art of great drugmaking. Drugmaking is not a statistical event, or simply a high-throughput industrialized pursuit. Microbia has developed a process for creating and selecting novel drug candidates that integrates the most successful drugmaking practices of the past and the best of today's cutting-edge technologies. Through this innovative discovery process, we are developing medicines that target important human needs. This process has yielded our two clinical programs and a robust preclinical pipeline. We ask the tough questions early. Microbia tackles the most difficult aspects of drugmaking: the interface of pharmacology and chemistry. We require our programs to have a pharmacologically validated mechanism along with robust readouts that are predictive of clinical outcomes. This commitment positions Microbia to rapidly iterate between in vivo models and chemistry to quickly find lead molecules with clinical promise.